Mertens, Beatrijs
Wauters, Joost
Debaveye, Yves
Van Regenmortel, Niels
Degezelle, Karlien
Meersseman, Philippe
Hermans, Greet
Vandenbriele, Christophe
Van Daele, Ruth
Spriet, Isabel
Article History
Received: 17 June 2022
Accepted: 5 July 2022
First Online: 27 July 2022
Declarations
:
: The study was approved by the Ethics Committee Research UZ/KU Leuven (S65215). Not applicable.
: Not applicable.
: JW reports investigator-initiated grants from Pfizer, Gilead and MSD; consulting fees from Pfizer and Gilead; speakers’ fees from Pfizer, Gilead and MSD; travel fees from Pfizer, Gilead and MSD; participation in advisory boards of Pfizer and Gilead; receipt of study drugs from MSD, outside the submitted work. YD reports speakers’ and travel fees from Pfizer and participation in advisory boards of Pfizer, outside the submitted work. GH is supported by the Flanders Research Foundation (FWO Vlaanderen) through a senior clinical research fellowship. IS is supported by the Clinical Research Fund of UZ Leuven and reports consulting fees from Pfizer and Cidara; speakers’ fees from Pfizer; travel fees from Pfizer, outside the submitted work. BM, NVR, KD, PM, CVDB and RVD have no conflicts of interest to declare related to this work.